Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

David Meurisse

Contributor / Partner
share with twitter share with LinkedIn share with facebook
share via e-mail

Expectation of a turn-around

Strategy published on 11/18/2016 | 15:02
long trade
Stop-loss triggered
Entry price : 31.95$ | Target : 36.9$ | Stop-loss : 30.7$ | Potential : 15.49%
The recent downside mouvement appears to lose momentum which could allow Pfizer Inc. shares to regain a positive medium term outlook.
Investors have an opportunity to buy the stock and target the $ 36.9.
  • The company has poor fundamentals for a short-term investment strategy.

  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 29.89 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Historically, the company has been releasing figures that are above expectations.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

  • With an enterprise value anticipated at 4.23 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last few months, analysts have been revising downwards their earnings forecast.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 54 435 M
EBIT 2018 20 816 M
Net income 2018 12 806 M
Debt 2018 27 450 M
Yield 2018 3,74%
P/E ratio 2018 16,76
P/E ratio 2019 15,49
EV / Sales 2018 4,53x
EV / Sales 2019 4,24x
Capitalization 219 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Duration : Period : Week
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders